The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.
 
Jonathan W. Riess
Consulting or Advisory Role - BeiGene; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Daiichi Sankyo; EMD Serono; Genentech; Janssen Oncology; Jazz Pharmaceuticals; Novartis; Regeneron; Teladoc; Turning Point Therapeutics
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Revolution Medicines (Inst); Spectrum Pharmaceuticals (Inst)
 
Mark D. Krailo
Consulting or Advisory Role - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Sukhmani Kaur Padda
Honoraria - CME Solutions; Janssen; Jazz Pharmaceuticals; MECC Global Meetings; Medical Oncology Association of Southern California; Nanobiotix; Physicans' Education Resource
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Blueprint Medicines; G1 Therapeutics; Genentech; Genzyme; Janssen Oncology; Jazz Pharmaceuticals; Mirati Therapeutics
Research Funding - Bayer (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); EpicentRx (Inst)
Other Relationship - OncLive/MJH Life Sciences
 
Susan G. Groshen
No Relationships to Disclose
 
Heather A. Wakelee
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Mirati Therapeutics
Research Funding - ACEA Biosciences (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Helsinn Therapeutics (Inst); Merck (Inst); Novartis (Inst); Seagen (Inst); Xcovery (Inst)
(OPTIONAL) Uncompensated Relationships - Genentech/Roche; Merck
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; Genentech; GlaxoSmithKline; Janssen Oncology; Lilly; Merck KGaA; Mirati Therapeutics; Seagen; Takeda; Tesaro
Research Funding - Blueprint Medicines; Calithera Biosciences (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst)
 
Marianna Koczywas
Speakers' Bureau - AstraZeneca; Celgene
 
Zofia Piotrowska
Consulting or Advisory Role - Blueprint Medicines; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo Europe GmbH; Janssen; Jazz Pharmaceuticals; Takeda
Research Funding - Abbvie (Inst); ARIAD/Takeda (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Cullinan Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); GlaxoSmithKline/Tesaro (Inst); Janssen Oncology (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca/MedImmune
 
Conor Ernst Steuer
Honoraria - Merck
Consulting or Advisory Role - Abbvie; ARMO BioSciences; BerGenBio; Caris Life Sciences; Lilly; Mirati Therapeutics; Sanofi/Regeneron
Research Funding - Daiichi Sankyo; Infinity Pharmaceuticals; Seagen; Vaccinex
 
Chul Kim
Consulting or Advisory Role - Janssen; Novartis
Research Funding - AstraZeneca; Bristol-Myers Squibb; Debiopharm Group; Janssen; Karyopharm Therapeutics; Novartis; Regeneron; Tesaro
 
Cloud P. Paweletz
Stock and Other Ownership Interests - Akouos (I); Xsphera Biosciences
Honoraria - Bio-Rad
Consulting or Advisory Role - DropWorks; Xsphera Biosciences
Research Funding - Bicara Therapeutics; Bolt Biotherapeutics; Bristol-Meyers Squibb; CUE Biopharma; Daiichi Sankyo; Intellia Therapeutics; Janssen Oncology; Mirati Therapeutics; Resolution Bioscience; Takeda; TargImmune Therapeutics
 
Lynette M. Sholl
Stock and Other Ownership Interests - Moderna Therapeutics (I)
Consulting or Advisory Role - Genentech (Inst); Lilly (Inst)
Research Funding - Roche/Genentech (Inst)
 
Grace Heavey
No Relationships to Disclose
 
Jill Kolesar
Stock and Other Ownership Interests - Helix Diagnostics
Consulting or Advisory Role - The Jackson Laboratory
Research Funding - ArtemiLife
Patents, Royalties, Other Intellectual Property - Patent pending for a cell based therapy derived from human macrophages
 
Jeffrey Moscow
No Relationships to Disclose
 
Pasi A. Janne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals; Loxo
Consulting or Advisory Role - Abbvie; Accutar Biotech; Allorion Therapeutics; Araxes Pharma; AstraZeneca; Bayer; Biocartis; Biocartis; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; Ignyta; Lilly; LOXO; Merrimack; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche/Genentech; Sanofi; SFJ Pharmaceuticals Group; Silicon Therapeutics; Syndax; Takeda; Transcenta; Voronoi Health Analytics
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Lilly; Puma Biotechnology; Revolution Medicines; Takeda
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention
 
Primo "Lucky" N. Lara
Consulting or Advisory Role - Calithera Biosciences (Inst); Janssen
Research Funding - Janssen Biotech (Inst); Taiho Pharmaceutical (Inst)
 
Edward M. Newman
No Relationships to Disclose
 
David R. Gandara
Honoraria - Amgen; Merck
Consulting or Advisory Role - Adagene (Inst); AstraZeneca (Inst); Daiichi Sankyo Alliance; Guardant Health (Inst); Guardant Health (Inst); IO Biotech (Inst); Lilly; Novartis; Ocean Genomics (Inst); OncoCyte (Inst); OncoHost (Inst); Roche/Genentech (Inst); Sanofi
Research Funding - Amgen (Inst); AstraZeneca (Inst); Genentech (Inst); Merck (Inst)